Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Arovella Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: MDMA for PTSD hits roadblock with FDA; and recent ASX cannabis stock winners
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 1
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Closing Bell: ASX loses its bottle, but Gold50 shows some Gallium to advance 50pc
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Health & Biotech
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
Health & Biotech
ASX Health Winners January: ‘Invest in business not science’, as SHG and PAA top winners list
Health & Biotech
ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: ASX 200 banks sixth straight win after Energy stocks drive investors mildly bananas
Health & Biotech
Weed Week: Blow to cannabis as Thailand backpedals on weed law; and recent ASX pot stock winners
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
ASX Biotech October Winners: Dimerix, Noxopharm and Chimeric dominate as investors hunt next big thing in pharma
Health & Biotech
